{"nctId":"NCT00306787","briefTitle":"Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes","startDateStruct":{"date":"2006-03"},"conditions":["Genital Herpes"],"count":1179,"armGroups":[{"label":"Famciclovir","type":"EXPERIMENTAL","interventionNames":["Drug: Famciclovir","Drug: Placebo matching valacyclovir"]},{"label":"Valacyclovir","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valacyclovir","Drug: Placebo matching famciclovir"]}],"interventions":[{"name":"Famciclovir","otherNames":["Famvir"]},{"name":"Valacyclovir","otherNames":["Valtrex"]},{"name":"Placebo matching famciclovir","otherNames":[]},{"name":"Placebo matching valacyclovir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* History of at least 4 recurrences of genital herpes in the preceding 12 months\n* Lesions located on the external genitalia or anogenital region\n* Willing to discontinue suppressive treatment\n* Documented positive herpes simplex virus (HSV)\n* General good health, and history of normal renal function\n\nExclusion Criteria:\n\n* Women of childbearing potential not using approved form of contraceptive\n* Pregnant or nursing women\n* History of hypersensitivity to famciclovir, valacyclovir, or acyclovir\n* Known to be immunosuppressed\n* Known to have renal dysfunction\n* Receiving anti-herpes therapy\n* Known to have other genital tract disorders\n* Known to have condition which could interfere with drug absorption\n\nAdditional protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Investigator-assessed Time to Healing of All Non-aborted Genital Herpes Lesions","description":"Time to healing of all non-aborted genital herpes lesions was defined as the time from the first dose of study drug taken no earlier than the recurrence of genital herpes to the investigator-assessed time of healing (i.e. loss of all crusts and re-epithelialization of the lesions; erythema could have been present). Non-aborted lesions are lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing. The median time was estimated using Kaplan-Meier method by censoring missing values at the time of last clinical lesion observation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.25","spread":null},{"groupId":"OG001","value":"4.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Aborted Genital Herpes Lesions","description":"Lesions that developed no further than the papule stage (erythema may have been present) were considered as aborted lesions. Prodrome also was considered the sign of aborted lesions in this study. Lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing were considered as non-aborted lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed Time to Healing of All (Non-aborted and Aborted) Genital Herpes Lesions","description":"Lesions that developed no further than the papule stage (erythema may have been present) were considered as aborted lesions. Prodrome also was considered the sign of aborted lesions in this study. Lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing were considered as non-aborted lesions. The median time was estimated using Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","spread":null},{"groupId":"OG001","value":"3.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of Symptoms Associated With Recurrent Genital Herpes","description":"Kaplan-Meier estimated time in hours of the resolution of all symptoms (pain, burning, itching, tingling and tenderness) associated with recurrent genital herpes. Kaplan-Meier method is used to estimate the time to resolution of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"48.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Second Recurrence of Genital Herpes","description":"Patients who experienced a first recurrence of genital herpes and took study medication were followed for a period of up to 6 months to the second recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"342","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to a Second Recurrence of Genital Herpes","description":"Patients who experienced a first recurrence of genital herpes and took study medication were followed for a period of up to 6 months to the second recurrence. Time to a second recurrence of genital herpes was calculated in 2 ways as follows:\n\n1. From the date of treatment initiation no earlier than the recurrence of genital herpes to the date of onset for the second recurrence, or\n2. From the date of healing of non-aborted lesions or confirmation of aborted lesions to the date of onset for the second recurrence.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":null},{"groupId":"OG001","value":"38.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":371},"commonTop":["Headache","Nausea","Diarrhea","Vomiting","Abdominal pain"]}}}